JP2002523375A5 - - Google Patents

Download PDF

Info

Publication number
JP2002523375A5
JP2002523375A5 JP2000565916A JP2000565916A JP2002523375A5 JP 2002523375 A5 JP2002523375 A5 JP 2002523375A5 JP 2000565916 A JP2000565916 A JP 2000565916A JP 2000565916 A JP2000565916 A JP 2000565916A JP 2002523375 A5 JP2002523375 A5 JP 2002523375A5
Authority
JP
Japan
Prior art keywords
use according
human
risk
daily dose
human patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000565916A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002523375A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/018961 external-priority patent/WO2000010596A1/en
Publication of JP2002523375A publication Critical patent/JP2002523375A/ja
Publication of JP2002523375A5 publication Critical patent/JP2002523375A5/ja
Pending legal-status Critical Current

Links

JP2000565916A 1998-08-19 1999-08-19 骨の靭性、及び、剛性を増し、骨折を減少させる方法 Pending JP2002523375A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9715198P 1998-08-19 1998-08-19
US60/097,151 1998-08-19
US9974698P 1998-09-10 1998-09-10
US60/099,746 1998-09-10
PCT/US1999/018961 WO2000010596A1 (en) 1998-08-19 1999-08-19 Method of increasing bone toughness and stiffness and reducing fractures

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010244314A Division JP2011021035A (ja) 1998-08-19 2010-10-29 骨の靭性、及び、剛性を増し、骨折を減少させる方法

Publications (2)

Publication Number Publication Date
JP2002523375A JP2002523375A (ja) 2002-07-30
JP2002523375A5 true JP2002523375A5 (enExample) 2009-01-29

Family

ID=26792729

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2000565916A Pending JP2002523375A (ja) 1998-08-19 1999-08-19 骨の靭性、及び、剛性を増し、骨折を減少させる方法
JP2010244314A Withdrawn JP2011021035A (ja) 1998-08-19 2010-10-29 骨の靭性、及び、剛性を増し、骨折を減少させる方法
JP2014061763A Expired - Lifetime JP6177718B2 (ja) 1998-08-19 2014-03-25 骨の靭性、及び、剛性を増し、骨折を減少させる方法
JP2014204577A Withdrawn JP2015028065A (ja) 1998-08-19 2014-10-03 骨の靭性、及び、剛性を増し、骨折を減少させる方法
JP2017124301A Withdrawn JP2017190332A (ja) 1998-08-19 2017-06-26 骨の靭性、及び、剛性を増し、骨折を減少させる方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2010244314A Withdrawn JP2011021035A (ja) 1998-08-19 2010-10-29 骨の靭性、及び、剛性を増し、骨折を減少させる方法
JP2014061763A Expired - Lifetime JP6177718B2 (ja) 1998-08-19 2014-03-25 骨の靭性、及び、剛性を増し、骨折を減少させる方法
JP2014204577A Withdrawn JP2015028065A (ja) 1998-08-19 2014-10-03 骨の靭性、及び、剛性を増し、骨折を減少させる方法
JP2017124301A Withdrawn JP2017190332A (ja) 1998-08-19 2017-06-26 骨の靭性、及び、剛性を増し、骨折を減少させる方法

Country Status (32)

Country Link
US (2) US6977077B1 (enExample)
EP (3) EP1059933B1 (enExample)
JP (5) JP2002523375A (enExample)
KR (1) KR100454207B1 (enExample)
CN (1) CN1205997C (enExample)
AR (1) AR033639A1 (enExample)
AT (1) ATE231000T1 (enExample)
AU (1) AU746277B2 (enExample)
BR (1) BR9909445A (enExample)
CA (1) CA2325371C (enExample)
CO (1) CO5130020A1 (enExample)
CY (2) CY1113343T1 (enExample)
CZ (1) CZ301017B6 (enExample)
DE (2) DE15152726T1 (enExample)
DK (4) DK1059933T3 (enExample)
DZ (1) DZ2873A1 (enExample)
EA (1) EA003362B1 (enExample)
ES (4) ES2190244T3 (enExample)
HR (1) HRP20000755A2 (enExample)
HU (2) HU1200430D0 (enExample)
ID (1) ID29039A (enExample)
IL (2) IL138829A0 (enExample)
MY (1) MY129227A (enExample)
NO (2) NO323984B1 (enExample)
NZ (1) NZ507056A (enExample)
PE (1) PE20001089A1 (enExample)
PL (1) PL201688B1 (enExample)
PT (4) PT1059933E (enExample)
TR (1) TR200003455T2 (enExample)
TW (1) TW576747B (enExample)
UA (1) UA72205C2 (enExample)
WO (1) WO2000010596A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
AR033639A1 (es) 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US20040033950A1 (en) 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
WO2001022093A1 (en) * 1999-09-20 2001-03-29 Eli Lilly And Company Method for monitoring treatment with a parathyroid hormone
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
AU2003207512B2 (en) * 2002-01-10 2008-06-12 Osteotrophin Llc Treatment of bone disorders with skeletal anabolic drugs
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
NZ545803A (en) * 2003-09-19 2008-03-28 Wisconsin Alumni Res Found Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and parathyroid hormone
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
US7244709B2 (en) * 2004-05-10 2007-07-17 Nastech Pharamecutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
MXPA06013168A (es) 2004-05-13 2007-05-15 Johnson & Johnson Aparato y metodo para el suministro transdermico de agentes de la hormona paratiroidea.
US7648965B2 (en) 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US20060069021A1 (en) * 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
CA2608016A1 (en) * 2005-05-11 2006-11-23 Unigene Laboratories, Inc. Improving bone formation and preservation by surgically inducing an increase in osteoblast activity coupled with the effect of administering pthrp or cgrp
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
WO2007059470A2 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
US20080119408A1 (en) * 2006-07-07 2008-05-22 Nastech Pharmaceutical Company Inc. Pth formulations for intranasal delivery
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
WO2008125655A1 (en) 2007-04-13 2008-10-23 Kuros Biosurgery Ag Polymeric tissue sealant
US20110137243A1 (en) * 2007-09-06 2011-06-09 Abbott Cardiovascular Systems Inc. Coating On A Balloon Device
US9457056B2 (en) * 2007-12-04 2016-10-04 Ben-Gurion University Of The Negev Research And Development Authority Peptides comprising alternating hydrophobic and anionic amino acids for treatment of osteoporosis
EP2227263A2 (en) 2007-12-28 2010-09-15 Kuros Biosurgery AG Pdgf fusion proteins incorporated into fibrin foams
ES2662018T3 (es) 2009-09-09 2018-04-05 Asahi Kasei Pharma Corporation Agente terapéutico/profiláctico que contiene PTH para la osteoporosis, caracterizado porque la PTH se administra una vez por semana en una dosis unitaria de 200 unidades
WO2011071480A1 (en) 2009-12-07 2011-06-16 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US9295663B2 (en) 2010-07-14 2016-03-29 Abbott Cardiovascular Systems Inc. Drug coated balloon with in-situ formed drug containing microspheres
WO2012111852A1 (ja) * 2011-02-17 2012-08-23 帝人ファーマ株式会社 椎体骨折治療剤及びその評価方法
ES2882852T3 (es) 2011-03-16 2021-12-02 Kuros Biosurgery Ag Formulación farmacéutica para la utilización en la fusión espinal
CN108195965B (zh) 2011-06-07 2021-02-23 旭化成制药株式会社 含pth肽冷冻干燥制剂的检査方法及包含该含pth肽冷冻干燥制剂的医药品的制造方法
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN108601833B (zh) * 2016-02-01 2022-11-15 伊莱利利公司 甲状旁腺激素-抗rankl抗体融合化合物
JP2020506926A (ja) * 2017-02-01 2020-03-05 ザ・ジョンズ・ホプキンス・ユニバーシティ 副甲状腺ホルモンと変性椎間板疾患の再生
US20200289621A1 (en) * 2017-09-22 2020-09-17 Asahi Kasei Pharma Corporation Teriparatide-containing liquid pharmaceutical composition having excellent stability
CN111447943A (zh) 2018-10-29 2020-07-24 旭化成制药株式会社 以按每周2次的频率给予特立帕肽或其盐为特征的骨质疏松症的预防或治疗方法
US12344649B2 (en) 2019-08-09 2025-07-01 Flagship Pioneering Innovations Vi, Llc Modulators of parathyroid hormone receptor (PTHR1)
GB2590692A (en) * 2019-12-24 2021-07-07 Corthotec Ltd Composition for improved bone fracture healing

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
DE3935738A1 (de) 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
US5208041A (en) 1991-05-23 1993-05-04 Allelix Biopharmaceuticals Inc. Essentially pure human parathyroid hormone
US5556940A (en) 1994-06-20 1996-09-17 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
JPH0873376A (ja) * 1994-09-07 1996-03-19 Asahi Chem Ind Co Ltd 骨粗鬆症治療薬
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
EP0800405A4 (en) * 1994-12-19 1998-11-11 Beth Israel Hospital CONTINUOUS ADMINISTRATION OF LOW DOSES OF HORMONE PARATHYRO DIENNE OR ITS AGONIST
EP1283035A3 (en) * 1994-12-22 2003-03-19 AstraZeneca AB Therapeutic preparation for inhalation containing parathyroid hormone
JPH08310965A (ja) * 1995-05-16 1996-11-26 Chugai Pharmaceut Co Ltd 骨癒合促進剤
BR9812068A (pt) 1997-09-09 2000-09-26 Hoffmann La Roche Processo para a cicatrização óssea e restauração de fraturas e utilização de um análogo de polipeptìdeo de peptìdeo (pthrp) relacionado com hormÈnios de paratireóide e seus sais
MY120063A (en) 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
AR033639A1 (es) 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US6907597B1 (en) 2000-10-13 2005-06-14 Ati International Srl Method and apparatus for constructing an executable program in memory
US6967759B2 (en) 2001-12-31 2005-11-22 Texas Instruments Incorporated Pulse width modulation sequence generation
JP5796714B2 (ja) 2012-01-13 2015-10-21 株式会社リコー 定着装置及び画像形成装置
EP2949301B1 (en) 2014-05-27 2018-04-18 The Procter and Gamble Company Absorbent core with curved and straight absorbent material areas

Similar Documents

Publication Publication Date Title
AU762481C (en) Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders
ES2190244T3 (es) Uso de la hormona paratiroidea constituida por una secuencia de aminoacidos 1-34 de la hormona paratiroidea humana para reducir el riesco de fracturas oseas vertebrales y no vertebrales.
IL210851A0 (en) Pharmaceutical formulation for contraception and hormone-replacement therapy
RU2010105122A (ru) Композиции для ухода за полостью рта, продукты и способы применения
EP1570823A3 (en) Substained analgesia achieved with buprenorphine
CY1110287T1 (el) Χρηση της ανθρωπινης παραθυρεοειδους ορμονης
PL320614A1 (en) Alendronate preparations for oral administration
ATE522211T1 (de) Stabilisierte fibrat-mikropartikel
DE69225135D1 (de) Dosierungsform zur verzoegerten wirkstofffreisetzung
BRPI0108435B8 (pt) formulação e uso de entecavir de baixa dose
IL158777A0 (en) Orally administering parathyroid hormone and calcitonin
JP2003514025A5 (enExample)
EP0873751A3 (en) Pharmaceutical product for application to uterus mucosa
Bruguera et al. Immunogenicity of a recombinant hepatitis B vaccine in haemodialysis patients
US5286490A (en) Transdermal fluoride medication
CA2492378A1 (en) Modified amino acid for the inhibition of platelet aggregation
JP2004503471A5 (enExample)
Matsumoto et al. Effectiveness of bovine gallstone (Goou) and bear gall powder (Yutan) on chronic liver diseases: a preliminary report
CN103585460B (zh) 一种用于牙龈止血的填塞剂
CN101433576A (zh) 小儿止泻药膏
Tennant Jr (−)-α-Acetylmethadol for treatment of chronic pain patients who abuse opioids
Sánchez et al. Meclofenamate sodium, phenylbutazone, and naproxen in the treatment of degenerative joint disease. Report of a placebo-controlled double-blind clinical comparison
PT1265629E (pt) Utilizacao da hormona de crescimento em dose baixa
CZ5821U1 (cs) Farmaceutický přípravek pro léčení hernofilie a použití hormonu mestranolu
Mamedalieva et al. Status of the feto-placental system in pregnant women with a history of habitual abortion during complex therapy including metabolic correction